本文關(guān)鍵詞： 線(xiàn)粒體通透性轉(zhuǎn)換孔道 大黃酸 HepG2細(xì)胞 細(xì)胞凋亡　出處：《復(fù)旦大學(xué)》2014年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：肝癌是常見(jiàn)的惡性腫瘤,位于男性腫瘤致死率第二位,女性腫瘤致死率第三位。傳統(tǒng)的腫瘤治療方式效果有限,5年的生存率僅為3%-67%,因此尋找肝癌有效藥物治療方法十分必要。而中醫(yī)藥對(duì)改善肝癌患者癥狀、減少放化療毒性、提高生存質(zhì)量、延長(zhǎng)生存期等方面恰恰發(fā)揮著獨(dú)特的優(yōu)勢(shì)。大黃酸(4,5-二羥基蒽醌-2-羧酸)是提取自我國(guó)傳統(tǒng)中藥大黃和虎杖根莖中的有效成分,其抗癌作用機(jī)制己被大量研究證實(shí)。鑒于其對(duì)不同的腫瘤細(xì)胞(乳腺癌,宮頸癌,胃癌以及肝癌)的增殖抑制作用,推測(cè)其具有重要的臨床藥用價(jià)值,同時(shí)相關(guān)分子機(jī)制研究結(jié)果提示,線(xiàn)粒體依賴(lài)的內(nèi)源性凋亡通路有可能參與大黃酸誘導(dǎo)的細(xì)胞凋亡。Ca2+超載,氧化應(yīng)激,缺氧,細(xì)胞毒性藥物均可導(dǎo)致線(xiàn)粒體通透性孔道開(kāi)放與跨膜電位的消失,進(jìn)而誘導(dǎo)細(xì)胞凋亡。研究表明：線(xiàn)粒體通透性轉(zhuǎn)換孔道在腫瘤細(xì)胞凋亡中起關(guān)鍵作用。目前國(guó)內(nèi)外對(duì)大黃酸的研究雖多有報(bào)道,但未見(jiàn)其對(duì)線(xiàn)粒體生理性作用與凋亡誘導(dǎo)作用相關(guān)性的分析,因此進(jìn)一步探索大黃酸誘導(dǎo)人肝癌HepG2細(xì)胞的凋亡作用,并研究線(xiàn)粒體通透轉(zhuǎn)換孔道在大黃酸誘導(dǎo)細(xì)胞凋亡中的地位,具有極為重要藥理學(xué)意義。本研究采用HepG2細(xì)胞系及大鼠肝臟離體線(xiàn)粒體作為實(shí)驗(yàn)?zāi)Ｐ?通過(guò)測(cè)定HepG2細(xì)胞系線(xiàn)粒體膜電位及ATP水平變化、線(xiàn)粒體腫脹程度、Ca2+外泄程度分析大黃酸誘導(dǎo)HepG2細(xì)胞線(xiàn)粒體損傷作用及機(jī)制,采用流式細(xì)胞儀、Westernblot、熒光檢測(cè)以及TUNEL檢測(cè)技術(shù),系統(tǒng)研究線(xiàn)粒體通透性轉(zhuǎn)換孔道在大黃酸誘導(dǎo)肝癌HepG2細(xì)胞凋亡過(guò)程中的重要作用機(jī)制。結(jié)果表明：大黃酸可導(dǎo)致線(xiàn)粒體功能障礙、腫脹以及Ca2+外泄,這些作用呈劑量依賴(lài)性,并且可以被線(xiàn)粒體通透性轉(zhuǎn)換孔道抑制劑CsA完全抑制,提示大黃酸可直接作用于線(xiàn)粒體,導(dǎo)致線(xiàn)粒體通透性轉(zhuǎn)換孔道開(kāi)放以及線(xiàn)粒體功能障礙；大黃酸誘導(dǎo)的HepG2細(xì)胞凋亡作用可被CsA所阻斷,提示線(xiàn)粒體通透性轉(zhuǎn)換孔道在大黃酸介導(dǎo)肝癌細(xì)胞株凋亡中起著重要作用。綜上,本研究在國(guó)內(nèi)外率先闡明線(xiàn)粒體通透性轉(zhuǎn)換孔道在大黃酸誘導(dǎo)的HepG2細(xì)胞凋亡中起著關(guān)鍵性作用,HepG2細(xì)胞凋亡與線(xiàn)粒體依賴(lài)的內(nèi)源性凋亡通路有關(guān)。從而為大黃酸的輔助腫瘤治療提供細(xì)胞分子生物學(xué)理論基礎(chǔ),為發(fā)現(xiàn)大黃酸輔助肝癌治療的新靶標(biāo)和尋找腫瘤輔助治療同類(lèi)新藥提供生物學(xué)信息。
[Abstract]:Hepatocellular carcinoma (HCC) is a common malignant tumor, which is the second leading cause of tumor mortality in males and the third in females. The traditional tumor therapy has a limited effect, and the 5-year survival rate is only 3-67%. Therefore, it is necessary to find effective drug therapy for liver cancer. Traditional Chinese medicine can improve the symptoms of patients with liver cancer, reduce the toxicity of radiotherapy and chemotherapy, and improve the quality of life. The prolongation of survival time and other aspects play a unique advantage. Rhein 4- 5- dihydroxyanthraquinone-2-carboxylic acid is extracted from the traditional Chinese traditional Chinese medicine rhubarb and Polygonum cuspidatum rhizome active components. Its anti-cancer mechanism has been confirmed by a large number of studies. In view of its different tumor cells (breast cancer, cervical cancer, gastric cancer and liver cancer) proliferation inhibition, it is assumed that it has important clinical medicinal value. At the same time, the related molecular mechanism suggests that mitochondrial dependent endogenous apoptosis pathway may be involved in the apoptosis induced by Rhein, Ca 2 overload, oxidative stress, hypoxia. Cytotoxic drugs can lead to the opening of mitochondrial permeability channels and the disappearance of transmembrane potential. Studies show that mitochondrial permeability transition pore plays a key role in apoptosis of tumor cells. There are many reports about Rhein at home and abroad. However, there was no correlation between mitochondrial physiological and apoptosis-inducing effects, so the apoptosis of human hepatoma HepG2 cells induced by Rhein was further explored. It is of great pharmacological significance to study the role of mitochondrial permeability transition pore in the apoptosis induced by Rhein. In this study, HepG2 cell line and isolated rat liver mitochondria were used as the experimental model. The mitochondrial membrane potential and the level of ATP in HepG2 cell line were measured. The extent of mitochondrial swelling and the extent of Ca 2 release were analyzed to analyze the mechanism of mitochondrial damage induced by Rhein in HepG2 cells. Flow cytometry, fluorescence detection and TUNEL detection were used. The mechanism of mitochondrial permeability transition pore in the apoptosis of HepG2 cells induced by Rhein was systematically studied. The results showed that Rhein could lead to mitochondrial dysfunction. Swelling and Ca2 leakage, these effects are dose-dependent, and can be completely inhibited by mitochondrial permeability conversion pore inhibitor CsA, suggesting that Rhein can act directly on mitochondria. It leads to the opening of mitochondrial permeability transition channels and mitochondrial dysfunction. Rhein induced apoptosis of HepG2 cells can be blocked by CsA, suggesting that mitochondrial permeability transition pore plays an important role in Rhein mediated apoptosis of hepatoma cells. This study was the first to clarify that mitochondrial permeability transition channels play a key role in the apoptosis of HepG2 cells induced by Rhein. Apoptosis of HepG2 cells is related to mitochondrial dependent endogenous apoptotic pathway, which provides a theoretical basis of cellular molecular biology for the adjuvant tumor therapy of Rhein. It provides biological information for the discovery of new targets for Rhein-assisted liver cancer therapy and the search for similar new drugs for tumor adjuvant therapy.
【學(xué)位授予單位】：復(fù)旦大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類(lèi)號(hào)】：R96

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳進(jìn)軍;趙路;董玫;王思明;秦琪瑜;陳虎;史清文;;土木香根中5種倍半萜化合物抗肝癌活性的研究[J];癌變·畸變·突變;2010年06期

2 李寧;陳蘭美;張海濤;賈振斌;羅輝;;釕配合物[Ru(MeIm)_4(bpy)]~(2+)的合成及對(duì)人肝癌細(xì)胞株增殖的影響[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2012年11期

3 谷文靜;張新毅;付曉燕;;肝細(xì)胞癌形成的分子遺傳學(xué)研究進(jìn)展[J];廣東醫(yī)學(xué);2011年01期

4 鄒惠;李瑋;;抗血管生成藥物在晚期肝癌中的應(yīng)用進(jìn)展[J];國(guó)際消化病雜志;2011年03期

5 權(quán)美平;;13-甲基肉豆蔻酸抗腫瘤機(jī)制研究進(jìn)展[J];動(dòng)物醫(yī)學(xué)進(jìn)展;2013年09期

6 王錚華;梁統(tǒng);李濤;周克元;;山奈酚對(duì)人肝癌細(xì)胞Huh7生長(zhǎng)及凋亡的影響[J];廣東醫(yī)學(xué);2014年02期

7 李福娟;唐小云;桂金秋;王小花;李玉婷;張濤;石學(xué)魁;;紅花注射液對(duì)人肝癌HepG-2細(xì)胞AKT表達(dá)的影響[J];廣東醫(yī)學(xué);2014年10期

8 凌華毓;顧康生;;尼妥珠單抗聯(lián)合表阿霉素對(duì)人肝癌細(xì)胞株HepG2體外生長(zhǎng)的影響[J];臨床腫瘤學(xué)雜志;2011年02期

9 楊?lèi)?龔未;王偉偉;俞曉敏;胡松年;于軍;;寒冷誘導(dǎo)產(chǎn)熱時(shí)大鼠棕色脂肪能量代謝相關(guān)蛋白譜的變化(英文)[J];生物化學(xué)與生物物理進(jìn)展;2010年10期

10 黃振;;肝細(xì)胞肝癌分子靶向治療進(jìn)展[J];實(shí)用腫瘤雜志;2011年04期

相關(guān)博士學(xué)位論文 前6條

1 王東亮;華蟾素抗肝癌有效成分的篩選、鑒定及作用機(jī)制研究[D];山東大學(xué);2010年

2 齊芳華;華蟾素及其活性成分蟾毒靈和華蟾毒精誘導(dǎo)肝癌細(xì)胞凋亡的機(jī)制探討[D];山東大學(xué);2011年

3 蔣磊;TIEG1基因在TGF-β1介導(dǎo)肝癌細(xì)胞生長(zhǎng)抑制中的作用及抗腫瘤研究[D];浙江大學(xué);2009年

4 李玉春;MicroRNA相關(guān)單核苷酸多態(tài)性與原發(fā)性肝癌遺傳易感性研究[D];鄭州大學(xué);2012年

5 葉海燕;日本三角渦蟲(chóng)（Dugesia japonica）線(xiàn)粒體蛋白質(zhì)組、轉(zhuǎn)錄組研究[D];陜西師范大學(xué);2012年

6 蔣嘉睿;ELMO1表達(dá)調(diào)控肝細(xì)胞癌侵襲轉(zhuǎn)移的作用機(jī)制研究[D];中南大學(xué);2012年

相關(guān)碩士學(xué)位論文 前8條

1 任鵬飛;AHSG基因的原核表達(dá)及其在原發(fā)性肝癌診斷中的價(jià)值[D];鄭州大學(xué);2010年

2 凌華毓;尼妥珠單抗聯(lián)合表阿霉素對(duì)人肝癌細(xì)胞株HepG2體外生長(zhǎng)的影響[D];安徽醫(yī)科大學(xué);2011年

3 劉會(huì)娟;腫瘤相關(guān)抗原的抗體檢測(cè)在原發(fā)性肝癌診斷中的價(jià)值[D];鄭州大學(xué);2009年

4 尤楠;HNF4α在胎肝干細(xì)胞定向分化修復(fù)肝組織損傷中作用機(jī)理的研究[D];第四軍醫(yī)大學(xué);2010年

5 李杰;Arginase-1、Glypican-3、Hepatocyte paraffin antigen 1及α-fetoprotein在肝臟腫瘤診斷與鑒別診斷中的意義[D];中國(guó)人民解放軍軍醫(yī)進(jìn)修學(xué)院;2012年

6 張黎;小檗堿膽酸衍生物B4誘導(dǎo)SMMC-7721肝癌細(xì)胞凋亡機(jī)制[D];東北林業(yè)大學(xué);2013年

7 黃海娟;中藥肉豆蔻抗腫瘤活性部位篩選及體外抗腫瘤機(jī)制研究[D];青島科技大學(xué);2014年

8 孫勇;和田胡楊林土壤放線(xiàn)菌分離、鑒定及次生代謝產(chǎn)物研究[D];塔里木大學(xué);2015年

，

本文編號(hào)：1474792